Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today presented clinical and preclinical data from sutacimig in GT and FVIID at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France. This follows the presentation of new clinical data from HMB-002 in Von Willebrand disease and the announcement of the HMB-003 program on Sunday, July 12.
"People living with GT and FVIID face a stark reality: no approved prophylaxis, a lifetime of unpredictable bleeds, and treatment options that have changed little in decades," said Benny Sørensen, MD, PhD, CEO of Hemab. "The data we’ve presented at ISTH 2026 show how we're closing that gap: sutacimig's Phase 2 LTE results demonstrate sustained bleed reduction alongside a manageable safety and tolerability profile that has enabled FDA alignment on a Phase 3 dose and regimen. What underscores the relevance of these data is the real-world context supporting them. Natural history data from our GT360 and ATHN Transcends studies confirm that patients continue to bleed well into adulthood, prophylaxis remains critically underutilized, and the profound psychological toll—anxiety, isolation, diminished quality of life—extends far beyond bleed frequency.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.